Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and debilitating lung disease characterized by fibrosis or scarring of the lungs. It causes fibrosis or scarring in the lungs which makes it difficult to breathe. IPF is associated with inflammation and irreversible scarring or fibrosis (scarring) of lung tissue over time. The IPF patients experience breathlessness, a dry cough and tiredness. There are limited treatment options available for patients suffering from idiopathic pulmonary fibrosis. The standard treatments are antifibrotic drugs namely pirfenidone and nintedanib which can slow down the progression of lung scarring but cannot reverse it.
The global Idiopathic Pulmonary Fibrosis Market is estimated to be valued at Us$ 4825.57 Bn in 2023 and is expected to exhibit a CAGR Of 5.1% over the forecast period 2024 To 2031, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The development of novel therapies holds major market opportunity in the idiopathic pulmonary fibrosis market. There is a significant unmet medical need for development of therapies that can reverse the lung scarring and damage caused by idiopathic pulmonary fibrosis. The current treatment options of pirfenidone and nintedanib only slow down disease progression but do not cure the condition. Many companies are conducting clinical trials for development of new drug candidates such as tyrosine kinase inhibitors, immunotherapies and stem cell therapies which have potential to reverse the fibrosis in lungs. If successfully developed, these novel therapies can capture a major share of the idiopathic pulmonary fibrosis market and drive the market growth during the forecast period.
Porter's Analysis
Threat of new entrants: Low capital requirement in pharmaceutical industry and government support for research and development attracts new players. However, presence of established brands and need for extensive clinical trials acts as barriers.
Bargaining power of buyers: Individual consumers have low bargaining power due to rare disease condition and need for specialised treatment. Whereas government agencies and private insurance companies have high bargaining power due to ability to negotiate on bulk purchase and price control mechanisms.
Bargaining power of suppliers: Pharmaceutical raw material suppliers have moderate bargaining power due presence of several ingredient manufacturers and minimal switching cost. However, niche compounds manufacturing companies enjoy some pricing leverage.
Threat of new substitutes: No effective treatment alternatives currently available, limiting threat of substitutes. However, ongoing research on cell and gene therapies poses future substitutes threat.
Competitive rivalry: High as market dominated by few multinational brands investing heavily in clinical research and new product development. Intense non-price competition to gain market share and therapeutic area leadership.
SWOT Analysis
Strengths: Established brands, clinical trial expertise, strong distribution network and partnerships with healthcare providers and non-profits working on rare diseases.
Weaknesses: High research and development costs, lengthy drug development cycles, dependency on few therapeutic areas and potential side-effects of drugs.
Opportunities: Increasing IPF prevalence, growing access to diagnosis and care in developing markets, co-development partnerships to expand pipeline.
Threats: Pricing pressures, inability to obtain regulatory approvals, failure or delays in clinical trials, entry of generics post patent expiries.
Key Takeaways
The Global Idiopathic Pulmonary Fibrosis Market Demand is expected to witness high growth led by increasing disease visibility, diagnosis and treatment cost coverage. The global Idiopathic Pulmonary Fibrosis Market is estimated to be valued at US$ 4825.57 Bn in 2023 and is expected to exhibit a CAGR of 5.1% over the forecast period 2024 to 2031.
The United States dominates currently accounting for over 40% market share due to presence of sophisticated healthcare infrastructure, high treatment cost coverage and presence of leading pharmaceutical manufacturers. The Asia Pacific region is anticipated to witness fastest growth over the forecast period supported by large patient pool, improving access to healthcare and focus of global players to tap emerging markets potential through partnerships and branded generics.
Key players operating in the Idiopathic Pulmonary Fibrosis market are VISUfarma, Johnson & Johnson, Otsuka Holdings Co. Ltd., OASIS Medical, Novartis AG, Sentiss Pharma Pvt. Ltd., AbbVie Inc. (Allergan PLC), Bausch Health Companies Inc., Santen Pharmaceutical Co. Ltd., and Sun Pharmaceutical Industries Ltd., among others. The market is concentrated in nature with top three players accounting for over 60% share. Companies are focused on expanding their product portfolio through acquisitions and in-licensing deals as clinical research remains critical for market leadership amid patent expiries of established brands.
Get more insights on this topic :
